Assessment of the Efficacy of Commercially Available and Candidate Vaccines against a Pandemic H1N1 2009 Virus
Identifieur interne : 001381 ( PascalFrancis/Corpus ); précédent : 001380; suivant : 001382Assessment of the Efficacy of Commercially Available and Candidate Vaccines against a Pandemic H1N1 2009 Virus
Auteurs : Gary P. Kobinger ; Isabelle Meunier ; Ami Patel ; Stéphane Pillet ; Jason Gren ; Shane Stebner ; Anders Leung ; James L. Neufeld ; Darwyn Kobasa ; Veronika Von MesslingSource :
- The Journal of infectious diseases [ 0022-1899 ] ; 2010.
Descripteurs français
- Pascal (Inist)
English descriptors
- KwdEn :
Abstract
Background. The emergence and global spread of the pandemic H1N1 2009 influenza virus have raised questions regarding the protective effect of available seasonal vaccines and the efficacy of a newly produced matched vaccine. Methods. Ferrets were immunized with the 2008-2009 formulations of commercially available live attenuated (FluMist; MedImmune) or split-inactivated (Fluviral; GlaxoSmithKline) vaccines, a commercial swine vaccine (FluSure; Pfizer), or a laboratory-produced matched inactivated whole-virus vaccine (A/Mexico/InDRE4487/2009). Adaptive immune responses were monitored, and the animals were challenged with A/Mexico/InDRE4487/2009 after 5 weeks. Results. Only animals that received the swine or matched vaccines developed detectable hemagglutination-inhibiting antibodies against the challenge virus, whereas a T cell response was exclusively detected in animals vaccinated with FluMist. After challenge, all animals had high levels of virus replication in the upper respiratory tract. However, preexisting anti-pandemic H1N1 2009 antibodies resulted in reduced clinical signs and improved survival. Surprisingly, FluMist was associated with a slight increase in mortality and greater lung damage, which correlated with early up-regulation of interleukin-10. Conclusions. The present study demonstrates that a single dose of matched inactivated vaccine confers partial protection against a pandemic H1N1 2009 virus, and it suggests that a higher dose or prime-boost regimen may be required. The consequences of mismatched immunity to influenza merit further investigation.
Notice en format standard (ISO 2709)
Pour connaître la documentation sur le format Inist Standard.
pA |
|
---|
Format Inist (serveur)
NO : | PASCAL 10-0203512 INIST |
---|---|
ET : | Assessment of the Efficacy of Commercially Available and Candidate Vaccines against a Pandemic H1N1 2009 Virus |
AU : | KOBINGER (Gary P.); MEUNIER (Isabelle); PATEL (Ami); PILLET (Stéphane); GREN (Jason); STEBNER (Shane); LEUNG (Anders); NEUFELD (James L.); KOBASA (Darwyn); VON MESSLING (Veronika) |
AF : | Special Pathogens Program, National Microbiology Laboratory, Public Health Agency of Canada/Canada (1 aut., 3 aut., 5 aut., 6 aut., 7 aut., 9 aut.); Department of Medical Microbiology, University of Manitoba/Canada (1 aut., 3 aut., 9 aut.); National Centre for Foreign Animal Disease, Canadian Food Inspection Agency/Winnipeg, Manitoba/Canada (8 aut.); Institut National de la Recherche Scientifique-Institut Armand-Frappier, University of Quebec/Laval, Quebec/Canada (2 aut., 4 aut., 10 aut.) |
DT : | Publication en série; Niveau analytique |
SO : | The Journal of infectious diseases; ISSN 0022-1899; Coden JIDIAQ; Etats-Unis; Da. 2010; Vol. 201; No. 7; Pp. 1000-1006; Bibl. 25 ref. |
LA : | Anglais |
EA : | Background. The emergence and global spread of the pandemic H1N1 2009 influenza virus have raised questions regarding the protective effect of available seasonal vaccines and the efficacy of a newly produced matched vaccine. Methods. Ferrets were immunized with the 2008-2009 formulations of commercially available live attenuated (FluMist; MedImmune) or split-inactivated (Fluviral; GlaxoSmithKline) vaccines, a commercial swine vaccine (FluSure; Pfizer), or a laboratory-produced matched inactivated whole-virus vaccine (A/Mexico/InDRE4487/2009). Adaptive immune responses were monitored, and the animals were challenged with A/Mexico/InDRE4487/2009 after 5 weeks. Results. Only animals that received the swine or matched vaccines developed detectable hemagglutination-inhibiting antibodies against the challenge virus, whereas a T cell response was exclusively detected in animals vaccinated with FluMist. After challenge, all animals had high levels of virus replication in the upper respiratory tract. However, preexisting anti-pandemic H1N1 2009 antibodies resulted in reduced clinical signs and improved survival. Surprisingly, FluMist was associated with a slight increase in mortality and greater lung damage, which correlated with early up-regulation of interleukin-10. Conclusions. The present study demonstrates that a single dose of matched inactivated vaccine confers partial protection against a pandemic H1N1 2009 virus, and it suggests that a higher dose or prime-boost regimen may be required. The consequences of mismatched immunity to influenza merit further investigation. |
CC : | 002A05F04; 002B05; 002A05C10 |
FD : | Virus grippal A; Efficacité; Vaccin; Infection |
FG : | Influenzavirus A; Orthomyxoviridae; Virus |
ED : | Influenza A virus; Efficiency; Vaccine; Infection |
EG : | Influenzavirus A; Orthomyxoviridae; Virus |
SD : | Influenza A virus; Eficacia; Vacuna; Infección |
LO : | INIST-2052.354000181584600070 |
ID : | 10-0203512 |
Links to Exploration step
Pascal:10-0203512Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">Assessment of the Efficacy of Commercially Available and Candidate Vaccines against a Pandemic H1N1 2009 Virus</title>
<author><name sortKey="Kobinger, Gary P" sort="Kobinger, Gary P" uniqKey="Kobinger G" first="Gary P." last="Kobinger">Gary P. Kobinger</name>
<affiliation><inist:fA14 i1="01"><s1>Special Pathogens Program, National Microbiology Laboratory, Public Health Agency of Canada</s1>
<s3>CAN</s3>
<sZ>1 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>9 aut.</sZ>
</inist:fA14>
</affiliation>
<affiliation><inist:fA14 i1="02"><s1>Department of Medical Microbiology, University of Manitoba</s1>
<s3>CAN</s3>
<sZ>1 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>9 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Meunier, Isabelle" sort="Meunier, Isabelle" uniqKey="Meunier I" first="Isabelle" last="Meunier">Isabelle Meunier</name>
<affiliation><inist:fA14 i1="04"><s1>Institut National de la Recherche Scientifique-Institut Armand-Frappier, University of Quebec</s1>
<s2>Laval, Quebec</s2>
<s3>CAN</s3>
<sZ>2 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>10 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Patel, Ami" sort="Patel, Ami" uniqKey="Patel A" first="Ami" last="Patel">Ami Patel</name>
<affiliation><inist:fA14 i1="01"><s1>Special Pathogens Program, National Microbiology Laboratory, Public Health Agency of Canada</s1>
<s3>CAN</s3>
<sZ>1 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>9 aut.</sZ>
</inist:fA14>
</affiliation>
<affiliation><inist:fA14 i1="02"><s1>Department of Medical Microbiology, University of Manitoba</s1>
<s3>CAN</s3>
<sZ>1 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>9 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Pillet, Stephane" sort="Pillet, Stephane" uniqKey="Pillet S" first="Stéphane" last="Pillet">Stéphane Pillet</name>
<affiliation><inist:fA14 i1="04"><s1>Institut National de la Recherche Scientifique-Institut Armand-Frappier, University of Quebec</s1>
<s2>Laval, Quebec</s2>
<s3>CAN</s3>
<sZ>2 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>10 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Gren, Jason" sort="Gren, Jason" uniqKey="Gren J" first="Jason" last="Gren">Jason Gren</name>
<affiliation><inist:fA14 i1="01"><s1>Special Pathogens Program, National Microbiology Laboratory, Public Health Agency of Canada</s1>
<s3>CAN</s3>
<sZ>1 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>9 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Stebner, Shane" sort="Stebner, Shane" uniqKey="Stebner S" first="Shane" last="Stebner">Shane Stebner</name>
<affiliation><inist:fA14 i1="01"><s1>Special Pathogens Program, National Microbiology Laboratory, Public Health Agency of Canada</s1>
<s3>CAN</s3>
<sZ>1 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>9 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Leung, Anders" sort="Leung, Anders" uniqKey="Leung A" first="Anders" last="Leung">Anders Leung</name>
<affiliation><inist:fA14 i1="01"><s1>Special Pathogens Program, National Microbiology Laboratory, Public Health Agency of Canada</s1>
<s3>CAN</s3>
<sZ>1 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>9 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Neufeld, James L" sort="Neufeld, James L" uniqKey="Neufeld J" first="James L." last="Neufeld">James L. Neufeld</name>
<affiliation><inist:fA14 i1="03"><s1>National Centre for Foreign Animal Disease, Canadian Food Inspection Agency</s1>
<s2>Winnipeg, Manitoba</s2>
<s3>CAN</s3>
<sZ>8 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Kobasa, Darwyn" sort="Kobasa, Darwyn" uniqKey="Kobasa D" first="Darwyn" last="Kobasa">Darwyn Kobasa</name>
<affiliation><inist:fA14 i1="01"><s1>Special Pathogens Program, National Microbiology Laboratory, Public Health Agency of Canada</s1>
<s3>CAN</s3>
<sZ>1 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>9 aut.</sZ>
</inist:fA14>
</affiliation>
<affiliation><inist:fA14 i1="02"><s1>Department of Medical Microbiology, University of Manitoba</s1>
<s3>CAN</s3>
<sZ>1 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>9 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Von Messling, Veronika" sort="Von Messling, Veronika" uniqKey="Von Messling V" first="Veronika" last="Von Messling">Veronika Von Messling</name>
<affiliation><inist:fA14 i1="04"><s1>Institut National de la Recherche Scientifique-Institut Armand-Frappier, University of Quebec</s1>
<s2>Laval, Quebec</s2>
<s3>CAN</s3>
<sZ>2 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>10 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">INIST</idno>
<idno type="inist">10-0203512</idno>
<date when="2010">2010</date>
<idno type="stanalyst">PASCAL 10-0203512 INIST</idno>
<idno type="RBID">Pascal:10-0203512</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">001381</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">Assessment of the Efficacy of Commercially Available and Candidate Vaccines against a Pandemic H1N1 2009 Virus</title>
<author><name sortKey="Kobinger, Gary P" sort="Kobinger, Gary P" uniqKey="Kobinger G" first="Gary P." last="Kobinger">Gary P. Kobinger</name>
<affiliation><inist:fA14 i1="01"><s1>Special Pathogens Program, National Microbiology Laboratory, Public Health Agency of Canada</s1>
<s3>CAN</s3>
<sZ>1 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>9 aut.</sZ>
</inist:fA14>
</affiliation>
<affiliation><inist:fA14 i1="02"><s1>Department of Medical Microbiology, University of Manitoba</s1>
<s3>CAN</s3>
<sZ>1 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>9 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Meunier, Isabelle" sort="Meunier, Isabelle" uniqKey="Meunier I" first="Isabelle" last="Meunier">Isabelle Meunier</name>
<affiliation><inist:fA14 i1="04"><s1>Institut National de la Recherche Scientifique-Institut Armand-Frappier, University of Quebec</s1>
<s2>Laval, Quebec</s2>
<s3>CAN</s3>
<sZ>2 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>10 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Patel, Ami" sort="Patel, Ami" uniqKey="Patel A" first="Ami" last="Patel">Ami Patel</name>
<affiliation><inist:fA14 i1="01"><s1>Special Pathogens Program, National Microbiology Laboratory, Public Health Agency of Canada</s1>
<s3>CAN</s3>
<sZ>1 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>9 aut.</sZ>
</inist:fA14>
</affiliation>
<affiliation><inist:fA14 i1="02"><s1>Department of Medical Microbiology, University of Manitoba</s1>
<s3>CAN</s3>
<sZ>1 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>9 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Pillet, Stephane" sort="Pillet, Stephane" uniqKey="Pillet S" first="Stéphane" last="Pillet">Stéphane Pillet</name>
<affiliation><inist:fA14 i1="04"><s1>Institut National de la Recherche Scientifique-Institut Armand-Frappier, University of Quebec</s1>
<s2>Laval, Quebec</s2>
<s3>CAN</s3>
<sZ>2 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>10 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Gren, Jason" sort="Gren, Jason" uniqKey="Gren J" first="Jason" last="Gren">Jason Gren</name>
<affiliation><inist:fA14 i1="01"><s1>Special Pathogens Program, National Microbiology Laboratory, Public Health Agency of Canada</s1>
<s3>CAN</s3>
<sZ>1 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>9 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Stebner, Shane" sort="Stebner, Shane" uniqKey="Stebner S" first="Shane" last="Stebner">Shane Stebner</name>
<affiliation><inist:fA14 i1="01"><s1>Special Pathogens Program, National Microbiology Laboratory, Public Health Agency of Canada</s1>
<s3>CAN</s3>
<sZ>1 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>9 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Leung, Anders" sort="Leung, Anders" uniqKey="Leung A" first="Anders" last="Leung">Anders Leung</name>
<affiliation><inist:fA14 i1="01"><s1>Special Pathogens Program, National Microbiology Laboratory, Public Health Agency of Canada</s1>
<s3>CAN</s3>
<sZ>1 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>9 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Neufeld, James L" sort="Neufeld, James L" uniqKey="Neufeld J" first="James L." last="Neufeld">James L. Neufeld</name>
<affiliation><inist:fA14 i1="03"><s1>National Centre for Foreign Animal Disease, Canadian Food Inspection Agency</s1>
<s2>Winnipeg, Manitoba</s2>
<s3>CAN</s3>
<sZ>8 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Kobasa, Darwyn" sort="Kobasa, Darwyn" uniqKey="Kobasa D" first="Darwyn" last="Kobasa">Darwyn Kobasa</name>
<affiliation><inist:fA14 i1="01"><s1>Special Pathogens Program, National Microbiology Laboratory, Public Health Agency of Canada</s1>
<s3>CAN</s3>
<sZ>1 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>9 aut.</sZ>
</inist:fA14>
</affiliation>
<affiliation><inist:fA14 i1="02"><s1>Department of Medical Microbiology, University of Manitoba</s1>
<s3>CAN</s3>
<sZ>1 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>9 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Von Messling, Veronika" sort="Von Messling, Veronika" uniqKey="Von Messling V" first="Veronika" last="Von Messling">Veronika Von Messling</name>
<affiliation><inist:fA14 i1="04"><s1>Institut National de la Recherche Scientifique-Institut Armand-Frappier, University of Quebec</s1>
<s2>Laval, Quebec</s2>
<s3>CAN</s3>
<sZ>2 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>10 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
</analytic>
<series><title level="j" type="main">The Journal of infectious diseases</title>
<title level="j" type="abbreviated">J. infect. dis.</title>
<idno type="ISSN">0022-1899</idno>
<imprint><date when="2010">2010</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt><title level="j" type="main">The Journal of infectious diseases</title>
<title level="j" type="abbreviated">J. infect. dis.</title>
<idno type="ISSN">0022-1899</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Efficiency</term>
<term>Infection</term>
<term>Influenza A virus</term>
<term>Vaccine</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr"><term>Virus grippal A</term>
<term>Efficacité</term>
<term>Vaccin</term>
<term>Infection</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Background. The emergence and global spread of the pandemic H1N1 2009 influenza virus have raised questions regarding the protective effect of available seasonal vaccines and the efficacy of a newly produced matched vaccine. Methods. Ferrets were immunized with the 2008-2009 formulations of commercially available live attenuated (FluMist; MedImmune) or split-inactivated (Fluviral; GlaxoSmithKline) vaccines, a commercial swine vaccine (FluSure; Pfizer), or a laboratory-produced matched inactivated whole-virus vaccine (A/Mexico/InDRE4487/2009). Adaptive immune responses were monitored, and the animals were challenged with A/Mexico/InDRE4487/2009 after 5 weeks. Results. Only animals that received the swine or matched vaccines developed detectable hemagglutination-inhibiting antibodies against the challenge virus, whereas a T cell response was exclusively detected in animals vaccinated with FluMist. After challenge, all animals had high levels of virus replication in the upper respiratory tract. However, preexisting anti-pandemic H1N1 2009 antibodies resulted in reduced clinical signs and improved survival. Surprisingly, FluMist was associated with a slight increase in mortality and greater lung damage, which correlated with early up-regulation of interleukin-10. Conclusions. The present study demonstrates that a single dose of matched inactivated vaccine confers partial protection against a pandemic H1N1 2009 virus, and it suggests that a higher dose or prime-boost regimen may be required. The consequences of mismatched immunity to influenza merit further investigation.</div>
</front>
</TEI>
<inist><standard h6="B"><pA><fA01 i1="01" i2="1"><s0>0022-1899</s0>
</fA01>
<fA02 i1="01"><s0>JIDIAQ</s0>
</fA02>
<fA03 i2="1"><s0>J. infect. dis.</s0>
</fA03>
<fA05><s2>201</s2>
</fA05>
<fA06><s2>7</s2>
</fA06>
<fA08 i1="01" i2="1" l="ENG"><s1>Assessment of the Efficacy of Commercially Available and Candidate Vaccines against a Pandemic H1N1 2009 Virus</s1>
</fA08>
<fA11 i1="01" i2="1"><s1>KOBINGER (Gary P.)</s1>
</fA11>
<fA11 i1="02" i2="1"><s1>MEUNIER (Isabelle)</s1>
</fA11>
<fA11 i1="03" i2="1"><s1>PATEL (Ami)</s1>
</fA11>
<fA11 i1="04" i2="1"><s1>PILLET (Stéphane)</s1>
</fA11>
<fA11 i1="05" i2="1"><s1>GREN (Jason)</s1>
</fA11>
<fA11 i1="06" i2="1"><s1>STEBNER (Shane)</s1>
</fA11>
<fA11 i1="07" i2="1"><s1>LEUNG (Anders)</s1>
</fA11>
<fA11 i1="08" i2="1"><s1>NEUFELD (James L.)</s1>
</fA11>
<fA11 i1="09" i2="1"><s1>KOBASA (Darwyn)</s1>
</fA11>
<fA11 i1="10" i2="1"><s1>VON MESSLING (Veronika)</s1>
</fA11>
<fA14 i1="01"><s1>Special Pathogens Program, National Microbiology Laboratory, Public Health Agency of Canada</s1>
<s3>CAN</s3>
<sZ>1 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>9 aut.</sZ>
</fA14>
<fA14 i1="02"><s1>Department of Medical Microbiology, University of Manitoba</s1>
<s3>CAN</s3>
<sZ>1 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>9 aut.</sZ>
</fA14>
<fA14 i1="03"><s1>National Centre for Foreign Animal Disease, Canadian Food Inspection Agency</s1>
<s2>Winnipeg, Manitoba</s2>
<s3>CAN</s3>
<sZ>8 aut.</sZ>
</fA14>
<fA14 i1="04"><s1>Institut National de la Recherche Scientifique-Institut Armand-Frappier, University of Quebec</s1>
<s2>Laval, Quebec</s2>
<s3>CAN</s3>
<sZ>2 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>10 aut.</sZ>
</fA14>
<fA20><s1>1000-1006</s1>
</fA20>
<fA21><s1>2010</s1>
</fA21>
<fA23 i1="01"><s0>ENG</s0>
</fA23>
<fA43 i1="01"><s1>INIST</s1>
<s2>2052</s2>
<s5>354000181584600070</s5>
</fA43>
<fA44><s0>0000</s0>
<s1>© 2010 INIST-CNRS. All rights reserved.</s1>
</fA44>
<fA45><s0>25 ref.</s0>
</fA45>
<fA47 i1="01" i2="1"><s0>10-0203512</s0>
</fA47>
<fA60><s1>P</s1>
</fA60>
<fA61><s0>A</s0>
</fA61>
<fA64 i1="01" i2="1"><s0>The Journal of infectious diseases</s0>
</fA64>
<fA66 i1="01"><s0>USA</s0>
</fA66>
<fC01 i1="01" l="ENG"><s0>Background. The emergence and global spread of the pandemic H1N1 2009 influenza virus have raised questions regarding the protective effect of available seasonal vaccines and the efficacy of a newly produced matched vaccine. Methods. Ferrets were immunized with the 2008-2009 formulations of commercially available live attenuated (FluMist; MedImmune) or split-inactivated (Fluviral; GlaxoSmithKline) vaccines, a commercial swine vaccine (FluSure; Pfizer), or a laboratory-produced matched inactivated whole-virus vaccine (A/Mexico/InDRE4487/2009). Adaptive immune responses were monitored, and the animals were challenged with A/Mexico/InDRE4487/2009 after 5 weeks. Results. Only animals that received the swine or matched vaccines developed detectable hemagglutination-inhibiting antibodies against the challenge virus, whereas a T cell response was exclusively detected in animals vaccinated with FluMist. After challenge, all animals had high levels of virus replication in the upper respiratory tract. However, preexisting anti-pandemic H1N1 2009 antibodies resulted in reduced clinical signs and improved survival. Surprisingly, FluMist was associated with a slight increase in mortality and greater lung damage, which correlated with early up-regulation of interleukin-10. Conclusions. The present study demonstrates that a single dose of matched inactivated vaccine confers partial protection against a pandemic H1N1 2009 virus, and it suggests that a higher dose or prime-boost regimen may be required. The consequences of mismatched immunity to influenza merit further investigation.</s0>
</fC01>
<fC02 i1="01" i2="X"><s0>002A05F04</s0>
</fC02>
<fC02 i1="02" i2="X"><s0>002B05</s0>
</fC02>
<fC02 i1="03" i2="X"><s0>002A05C10</s0>
</fC02>
<fC03 i1="01" i2="X" l="FRE"><s0>Virus grippal A</s0>
<s2>NW</s2>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="ENG"><s0>Influenza A virus</s0>
<s2>NW</s2>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="SPA"><s0>Influenza A virus</s0>
<s2>NW</s2>
<s5>01</s5>
</fC03>
<fC03 i1="02" i2="X" l="FRE"><s0>Efficacité</s0>
<s5>05</s5>
</fC03>
<fC03 i1="02" i2="X" l="ENG"><s0>Efficiency</s0>
<s5>05</s5>
</fC03>
<fC03 i1="02" i2="X" l="SPA"><s0>Eficacia</s0>
<s5>05</s5>
</fC03>
<fC03 i1="03" i2="X" l="FRE"><s0>Vaccin</s0>
<s5>06</s5>
</fC03>
<fC03 i1="03" i2="X" l="ENG"><s0>Vaccine</s0>
<s5>06</s5>
</fC03>
<fC03 i1="03" i2="X" l="SPA"><s0>Vacuna</s0>
<s5>06</s5>
</fC03>
<fC03 i1="04" i2="X" l="FRE"><s0>Infection</s0>
<s5>07</s5>
</fC03>
<fC03 i1="04" i2="X" l="ENG"><s0>Infection</s0>
<s5>07</s5>
</fC03>
<fC03 i1="04" i2="X" l="SPA"><s0>Infección</s0>
<s5>07</s5>
</fC03>
<fC07 i1="01" i2="X" l="FRE"><s0>Influenzavirus A</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="01" i2="X" l="ENG"><s0>Influenzavirus A</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="01" i2="X" l="SPA"><s0>Influenzavirus A</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="02" i2="X" l="FRE"><s0>Orthomyxoviridae</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="02" i2="X" l="ENG"><s0>Orthomyxoviridae</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="02" i2="X" l="SPA"><s0>Orthomyxoviridae</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="03" i2="X" l="FRE"><s0>Virus</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="03" i2="X" l="ENG"><s0>Virus</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="03" i2="X" l="SPA"><s0>Virus</s0>
<s2>NW</s2>
</fC07>
<fN21><s1>137</s1>
</fN21>
<fN44 i1="01"><s1>OTO</s1>
</fN44>
<fN82><s1>OTO</s1>
</fN82>
</pA>
</standard>
<server><NO>PASCAL 10-0203512 INIST</NO>
<ET>Assessment of the Efficacy of Commercially Available and Candidate Vaccines against a Pandemic H1N1 2009 Virus</ET>
<AU>KOBINGER (Gary P.); MEUNIER (Isabelle); PATEL (Ami); PILLET (Stéphane); GREN (Jason); STEBNER (Shane); LEUNG (Anders); NEUFELD (James L.); KOBASA (Darwyn); VON MESSLING (Veronika)</AU>
<AF>Special Pathogens Program, National Microbiology Laboratory, Public Health Agency of Canada/Canada (1 aut., 3 aut., 5 aut., 6 aut., 7 aut., 9 aut.); Department of Medical Microbiology, University of Manitoba/Canada (1 aut., 3 aut., 9 aut.); National Centre for Foreign Animal Disease, Canadian Food Inspection Agency/Winnipeg, Manitoba/Canada (8 aut.); Institut National de la Recherche Scientifique-Institut Armand-Frappier, University of Quebec/Laval, Quebec/Canada (2 aut., 4 aut., 10 aut.)</AF>
<DT>Publication en série; Niveau analytique</DT>
<SO>The Journal of infectious diseases; ISSN 0022-1899; Coden JIDIAQ; Etats-Unis; Da. 2010; Vol. 201; No. 7; Pp. 1000-1006; Bibl. 25 ref.</SO>
<LA>Anglais</LA>
<EA>Background. The emergence and global spread of the pandemic H1N1 2009 influenza virus have raised questions regarding the protective effect of available seasonal vaccines and the efficacy of a newly produced matched vaccine. Methods. Ferrets were immunized with the 2008-2009 formulations of commercially available live attenuated (FluMist; MedImmune) or split-inactivated (Fluviral; GlaxoSmithKline) vaccines, a commercial swine vaccine (FluSure; Pfizer), or a laboratory-produced matched inactivated whole-virus vaccine (A/Mexico/InDRE4487/2009). Adaptive immune responses were monitored, and the animals were challenged with A/Mexico/InDRE4487/2009 after 5 weeks. Results. Only animals that received the swine or matched vaccines developed detectable hemagglutination-inhibiting antibodies against the challenge virus, whereas a T cell response was exclusively detected in animals vaccinated with FluMist. After challenge, all animals had high levels of virus replication in the upper respiratory tract. However, preexisting anti-pandemic H1N1 2009 antibodies resulted in reduced clinical signs and improved survival. Surprisingly, FluMist was associated with a slight increase in mortality and greater lung damage, which correlated with early up-regulation of interleukin-10. Conclusions. The present study demonstrates that a single dose of matched inactivated vaccine confers partial protection against a pandemic H1N1 2009 virus, and it suggests that a higher dose or prime-boost regimen may be required. The consequences of mismatched immunity to influenza merit further investigation.</EA>
<CC>002A05F04; 002B05; 002A05C10</CC>
<FD>Virus grippal A; Efficacité; Vaccin; Infection</FD>
<FG>Influenzavirus A; Orthomyxoviridae; Virus</FG>
<ED>Influenza A virus; Efficiency; Vaccine; Infection</ED>
<EG>Influenzavirus A; Orthomyxoviridae; Virus</EG>
<SD>Influenza A virus; Eficacia; Vacuna; Infección</SD>
<LO>INIST-2052.354000181584600070</LO>
<ID>10-0203512</ID>
</server>
</inist>
</record>
Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/PandemieGrippaleV1/Data/PascalFrancis/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001381 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PascalFrancis/Corpus/biblio.hfd -nk 001381 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien |wiki= Sante |area= PandemieGrippaleV1 |flux= PascalFrancis |étape= Corpus |type= RBID |clé= Pascal:10-0203512 |texte= Assessment of the Efficacy of Commercially Available and Candidate Vaccines against a Pandemic H1N1 2009 Virus }}
This area was generated with Dilib version V0.6.34. |